Chronic experimental allergic encephalomyelitis in guinea pigs: immunologic studies on the two major myelin proteins

Peptide determinants of myelin proteolipid protein (PLP) in autoimmune demyelinating disease: a review

This article reviews recent advances in understanding the role of myelin proteolipid protein (PLP) in autoimmune demyelination. It is drawn largely from work published within the last ten years and discusses the immunology of PLP in the historical context of what has been learned from extensive studies on the immune response to myelin basic protein (MBP). Despite the fact that PLP is the major protein constituent of mammalian myelin, its role in autoimmune demyelination has not been widely recognized. The lack of understanding about the immunology of PLP is a direct result of the biochemical characteristics of the protein. PLP is a highly hydrophobic membrane protein with limited aqueous solubility. The hydrophobicity of PLP has thwarted immunologic studies of the intact protein. Recent work has circumvented the technical obstacles of studying the intact protein by using soluble synthetic PLP peptides. This approach has rapidly resulted in a more definitive understanding of the immune response to PLP. Presently, the data indicate that: i) PLP is a major central nervous system (CNS) specific encephalitogen; ii) CD4+ T cell reactivity to discrete PLP peptide determinants can mediate the development of acute, chronic relapsing, and chronic progressive experimental autoimmune encephalomyelitis (EAE); and iii) T cell reactivity to multiple PLP determinants occurs in patients with multiple sclerosis (MS), the major human CNS demyelinating disease.

Differential susceptibility to experimental allergic encephalomyelitis (EAE) in genetically defined A+ and A- rabbits

Only one out of 57 A-/A- rabbits immunized with rat or guinea-pig myelin developed clinical signs suggestive of EAE. On the contrary, clinical signs of acute or chronic EAE were found in two thirds of the 102 A+/A+ and A+/A- rabbits immunized in the same way. About one third of the diseased animals had reversible acute EAE, another third died paralysed and the last third developed chronic progressive or relapsing EAE. Incidence and severity of EAE symptoms were positively correlated with age and no significant difference was observed between males and females. Cellular and humoral anti-myelin responses were stronger in A+ than in A- rabbits. Anti-A antibodies, on the contrary, were only detected in A- rabbits. The A+ rabbits did not make Anti-A at any time. Anti-A antibodies increased early, in A- rabbits, after immunization with myelin (11-30 days) and were later replaced by a low, but specific, anti-myelin response (60-90 days). The gene responsible for the susceptibility to EAE is autosomal and dominant over resistance. This gene must be closely linked to the A locus or might be the A gene itself. The low susceptibility of A- rabbits to the disease could be, in this last case, a consequence of the competition between the early anti-A and the normal anti-myelin immune responses, both induced by the injection of myelin.

Chronic experimental autoimmune encephalomyelitis in the guinea pig. Presence of anti-M2 antibodies in central nervous system tissue and the possible role of M2 autoantigen in the induction of the disease

Experimental autoimmune encephalomyelitis (EAE) can be transferred adoptively with T cells sensitized to the basic protein of myelin (BP). However, in the guinea pig, the chronic form of EAE has not been found to be inducible with BP alone, nor has it been adoptively transferred. An antibody response to the central nervous system (CNS) myelin autoantigens was looked for in serum and target CNS tissue in S13 guinea pigs with isologous CNS tissue-induced chronic EAE. Antibody activity was estimated by an immunoenzymatic technique and by autoradiography, using immunoprecipitated and electrophoresed relevant radiolabelled antigens. In serum, IgG antibody response to BP and M2 reached its maximum level 30 to 40 d after immunization and then declined progressively until it became undetectable. On the other hand, while anti-BP antibodies were seldom detected in CNS tissue acid extract, anti-M2 IgG antibodies were always present in CNS tissue of chronic EAE animals, and the amount of these antibodies were related to the severity of symptoms and lesions. No antibody response to proteolipid or to galactocerebroside was detected in serum or CNS tissue. BP-immunized controls showed no chronic EAE and no response to M2 in their serum or CNS tissue. Inasmuch as M2 has been shown to be a glycoprotein of CNS myelin, and anti-M2 antibodies to have a demyelinating property, the latter would be responsible for CNS tissue demyelination in chronic EAE. A shared role of BP and M2 in the induction of chronic EAE in the guinea pig is suggested.

Chronic-relapsing experimental allergic encephalomyelitis in strain-13 guinea pigs: cell-mediated immunity and IgG isoelectric focusing in myelin basic protein-liposome-treated and untreated animals

Juvenile strain-13 guinea pigs challenged with whole central nervous system (CNS) tissue in complete Freund's adjuvant (CFA) developed chronic-relapsing (CR) experimental allergic encephalomyelitis (EAE). The animals that recovered from the first clinical episode were divided into three groups. One group was left untreated, one group was treated with three intracardiac injections of 100 micrograms glutaraldehyde-fixed myelin basic protein (MBP)-liposomes (MBP-L-GA) given once a week, and one group was treated with cytochrome c-liposomes (CYC-L-GA). The animals treated with MBP-liposomes were very well protected against further relapses. In vitro proliferative responses of peripheral blood lymphocytes (PBL) were performed repeatedly on most animals. The lymphocytes exhibited excellent proliferative responses to MBP, proteolipid apoprotein (PLP) and whole myelin, as well as to purified protein derivative (PPD) and concanavalin-A (ConA). High proliferative responses were recorded over the entire period of observation which lasted 12-22 months, each time the animals were tested in remission or in full relapse. However, a sharp decrease in proliferative responses was observed in most animals when the assay was performed 24-48 h before to 24 h after entering a relapse. The results demonstrate the presence of long-term and sustained cell-mediated responses to two distinct neuroantigens, and show fluctuations of both neuroantigen-specific and nonspecific responses concordant with a well-defined phase of the disease. Isoelectric focusing and immunofixation was performed on sera and cerebrospinal fluids obtained at the time of sacrifice. The pattern showed clear oligoclonal IgG bands (OB) in the samples obtained from untreated, CYC-L-GA-treated as well as in the MBP-L-GA-treated animals.

Plasma immunoglobulin responses and disease severity in chronic relapsing experimental allergic encephalomyelitis

Plasma IgG, IgA and IgM responses in various stages of chronic relapsing experimental allergic encephalomyelitis (CR-EAE) were investigated by ELISA and rocket immunoelectrophoresis. Autoantibody levels were elevated in acute EAE but immunoglobulin responses were maximal in chronic disease. Plasma IgG and IgA specific for the whole cord, myelin and MBP correlated closely with the clinical signs of post-acute disease; in age-matched groups, levels were lower in animals in remission or with no further disease than in those in relapse or with a stable chronic disease course. Sequential sampling revealed a significant increase in neuroantigen-specific IgG (with MBP as the dominant autoantigen) during the onset of a relapse. Lipid-specific antibody levels were raised throughout CR-EAE but constituted only a small proportion of the total response against neural antigens. Determination of total immunoglobulin concentrations suggested a general suppression of IgG responses in guinea pigs in remission. The strong correlations found between antibody levels and the severity of chronic disease provide further evidence that antibody-mediated mechanisms can play a major role in the pathogenesis of CR-EAE.

Antibody responses in chronic relapsing experimental allergic encephalomyelitis: correlation of serum demyelinating activity with antibody titre to the myelin/oligodendrocyte glycoprotein (MOG)

Antibody responses to the myelin/oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP) were determined in the sera of Hartley guinea pigs with chronic relapsing experimental allergic encephalomyelitis (CREAE) using an enzyme-linked immunoassay. The sera were also tested for in vivo demyelinating activity by infusion into the subarachnoid space of normal rats. In contrast to the MBP titres, the anti-MOG antibody titres showed good correlation with the in vivo demyelinating activity of the sera (r = 0.91, P less than 0.001). This result suggests that antibodies directed against MOG may be involved in the pathogenesis of demyelination in CREAE.

Chronic relapsing experimental autoimmune encephalomyelitis. Transient presence in blood of lymphocytes sensitised to encephalitogen at onset of inflammatory relapses

Juvenile guinea pigs were immunised with homologous spinal cord and monitored daily over a 6-month period for neurological signs of chronic relapsing experimental autoimmune encephalomyelitis (CREAE). At various times animals were killed, numbers of leucocytes in their cerebrospinal fluid (CSF) quantified, and in vitro proliferative responses of blood lymphocytes to myelin basic protein (MBP) and its encephalitogenic nonapeptide (NP) determined. After recovering from initial acute clinical signs, animals suffered at least two major spontaneous relapses separated by remission periods of 4-5 weeks mean duration. In the early chronic phase, 5-12 weeks post-immunisation (pi), 63% of the animals recovered fully from relapses, whereas relatively irreversible neurological deficits predominated in the late chronic phase. During the acute and chronic phases, there was a highly significant correlation between clinical severity and CSF pleocytosis only in animals killed within 24 h of onset of a clinical exacerbation associated with more than 100 leucocytes/microliter of CSF. Guinea pigs with this degree of CSF pleocytosis were defined as suffering an inflammatory relapse. Blood lymphocytes responsive to MBP and NP were detected only in animals killed at the onset of clinical signs of either the acute or an inflammatory relapse. This dynamic relationship suggests that migration of encephalitogen-responsive lymphocytes via the blood to the central nervous system could produce certain relapses in CREAE. However, the relative paucity of CSF leucocytes in most animals killed during relapses between 15-26 weeks pi suggests that other factors may elicit neurological exacerbations in the late chronic phase.